|
|
|
 |
| |
| Carcinogenesis,
Teratogenesis & Mutagenesis
The forth Editorial Board
|
|
Li
Guo-li |
|
| |
|
Male,
han people, birthed at Tumen city in January
1957,a member of the Chinese communist party.
Graduated and get B.S.M from Yanbian medical
college in December 1982. Principal research
trend on oncopathology and diagnositic pathology.
Now as a leader of course of study on pathology
and pathophysiology in Yangzhou university,
director of the department of pathology, professor,
master advisor (a studying doctor), associate
director of pathology group in Yangzhou instiute
of medicine, a member of the malpractice appraisement
specialist treasury , a editor for <chinese
modern clinical medicine journal>, <carcinogenesis,
teratogenesis and mutagenesis>, <practice
clinical medicine journal> and so on. After
graduate as a teacher to be selected in alma
mater. In August 1984 called in Jilin medical
college, in 1988 and 1997 got advanced study
discern in Tongji medical university and Shanghai
medical university. In January 1999 promoted
professor. Since November 1992 successively
part time as an associate director of the department
of basic medicine, director in Jilin medical
college, vice dean of medical college in Beihua
university. In August 2001 to be introduced
in Yangzhou university medical college. Took
the lead to establish a evoked rat hepatoma
model with DENA and AFTB1 in china in 1990.
Applicating tumor hybrid cell to depress rat
experimental hepatoma obtained success in 1992.
Completed antihepatocarcinoma effect study with
lymphakines activated homogeneity splenocytes
in vivo and in vitro in 1998. P53 express in
liver cancer and clinical significance study
and study of P53 antisense RNA inhibit HCC cell
grow in 2001. For the past few years, taken
charge of complete scientific research 8 articles,
6 achievements have passed appraisement and
got government agency technology improvement
prizes, and more than 20 research papers have
been published. |
|
| |
|
|
|
| |
 |
| |
 |
| Cheng
Shujun is currently as a professor of Cancer
Institute (Hospital), Chinese Academy of Medical Sciences
& Peking Union Medical College, Beijing, China,
and Chief Scientist of both China State Key Basic
Research Project “Fundamental investigation of human
carcinogenesis and cancer therapy and prevention”
and Beijing key Cancer Research Project “Tumor biomarker
profiling and human cancer diagnosis and therapy”.
He worked as a visiting scientist in Laboratoire de
Medicine Experimental, Institute de la Recherches
Scientifiques sur le Cancer, France (1978-1981), and
in Department of Pathology, Medical College of Ohio,
USA (1986-1987). He has established a series of short-term
tests for the detection of environmental carcinogens
and anti-carcinogens in China. He was elected as a
Member, Chinese Academy of Engineering in 1999. Dr.
Cheng is the President of Chinese Environmental Mutagen
Society, and Vice President of China Anticancer Association.
He found that the tea catechins showed a significant
inhibitory effect against human genital condylomas
and inflammatory hyperplasia. Based on the invention,
he and his collaborators had received international
patents “Composition for treating condyloma acuminate”
in 1998. This invention had been approved to go for
clinical phase III trial by US FDA. As invited speakers,
Dr. Cheng has visited many institutes at foreign countries
and attended at international conferences. |
|
| |
|
